Palmoplantar Pustulosis - Pipeline Insight, 2024

This “Palmoplantar Pustulosis - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Palmoplantar Pustulosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Palmoplantar Pustulosis Understanding

Palmoplantar Pustulosis: Overview

Palmoplantar pustulosis (PPP) is a rare, recurrent inflammatory disorder. Affected individuals develop small to large sterile blisters filled with a yellow turbid liquid (pustules) on the palms of the hands and/or soles of the feet. The pustules may be painful and cause a burning feeling. The exact cause of PPP is not known. Researchers have determined that possible causes include smoking, bacterial infections (acute or chronic tonsillitis, dental infection, chronic sinusitis), contact allergies (mainly metals) and certain medications. The most common symptoms include: red and tender skin, blisters and pustules (fluid-filled bumps) on the palms of the hands and the soles of the feet, itchiness, pain, skin cracks, scaly skin, dry and thick skin. There’s no cure for palmoplantar pustulosis. Treatment may help to manage the symptoms.

Palmoplantar Pustulosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplantar Pustulosis pipeline landscape is provided which includes the disease overview and Palmoplantar Pustulosis treatment guidelines. The assessment part of the report embraces, in depth Palmoplantar Pustulosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplantar Pustulosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Palmoplantar Pustulosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmoplantar Pustulosis.

Palmoplantar Pustulosis Emerging Drugs Chapters

This segment of the Palmoplantar Pustulosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Palmoplantar Pustulosis Emerging Drugs

KHK4827 (Brodalumab): Kyowa Kirin Co. Ltd.

Brodalumab is a Human monoclonal antibody designed for the treatment of inflammatory diseases. Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. It is currently in Phase III stage of development for palmoplantar pustulosis.

Imsidolimab: AnaptysBio, INC.

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP). The study is a Phase II, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar Pustulosis.

Palmoplantar Pustulosis: Therapeutic Assessment

This segment of the report provides insights about the different Palmoplantar Pustulosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Palmoplantar Pustulosis

There are approx. 8+ key companies which are developing the therapies for Palmoplantar Pustulosis. The companies which have their Palmoplantar Pustulosis drug candidates in the most advanced stage, i.e. phase III include, Kyowa Kirin Co., Ltd.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Palmoplantar Pustulosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmoplantar Pustulosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Pustulosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmoplantar Pustulosis drugs.

Palmoplantar Pustulosis Report Insights

• Palmoplantar Pustulosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Palmoplantar Pustulosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Palmoplantar Pustulosis drugs?
• How many Palmoplantar Pustulosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmoplantar Pustulosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Palmoplantar Pustulosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Palmoplantar Pustulosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kyowa Kirin Co., Ltd.
• Aristea Therapeutics Inc.
• AnaptysBio, Inc.
• Boehringer Ingelheim
• Janssen Biotech

Key Products

• BI655310
• RIST4721-201
• KHK4827
• ANB019
• Guselkumab

This product will be delivered within 2 business days.